Stock listing

Hanover:19X Axsome Therapeutics, Inc. Aktie

German listing (Hanover) of Axsome Therapeutics, Inc. · home listing NASDAQ:AXSM

Follow Axsome Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:AXSM

$129.36 USD -4.64 (-3.5%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:AXSM

Past year -9.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$128.24 – $135.09 USDNov 20, 2026
Volume
811,750 sharesNov 20, 2026
Market cap
$6.80B USDAt the close on Nov 20, 2026 · price × 52.60M shares outstanding
52-week range
$123.00 – $260.19 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$144.6M USDMedian day 802,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Axsome Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AXSM · Home$129.36 USD-4.64 (-3.5%)811,750$134.00$135.09$128.24$134.00Close on Nov 20, 2026
LSE:0HKF$130.15 USD-5.05 (-3.7%)841$134.70$137.10$130.15$135.20Close on Nov 20, 2026
Frankfurt:19X€118.00 EUR-4.15 (-3.4%)—€121.35€121.35€118.00€122.15Close on Nov 20, 2026
Stuttgart:19X€117.20 EUR-6.35 (-5.1%)—€122.40€123.35€116.85€123.55Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AXSM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$129.36-4.64-3.5%$134.00$135.09$128.24811,750
$134.00-1.95-1.4%$135.65$136.62$131.56743,387
$135.95-1.06-0.8%$136.36$137.46$134.67518,111
$137.01-4.68-3.3%$141.25$141.70$136.33989,131
$141.69-2.68-1.9%$143.99$145.29$136.63972,538
$144.37-4.87-3.3%$148.07$150.34$144.01979,492
$149.24+8.27+5.9%$141.41$151.31$141.411,072,464
$140.97+7.01+5.2%$134.60$142.93$133.871,285,565
$133.96+1.59+1.2%$133.29$134.71$131.411,117,926
$132.37+2.57+2.0%$130.46$133.79$130.00718,345
$129.80-7.20-5.3%$137.00$137.56$128.991,109,346
$137.00-2.61-1.9%$140.56$140.56$134.381,034,191
$139.61+3.60+2.6%$136.88$145.50$136.881,679,392
$136.01-8.42-5.8%$136.50$138.03$123.002,716,703
$144.43+0.98+0.7%$143.23$146.17$131.272,090,305
$143.45-0.060.0%$146.06$147.49$140.42850,317
$143.51+1.31+0.9%$141.60$144.14$140.49738,719
$142.20-1.86-1.3%$143.99$145.44$141.151,104,340
$144.06-0.98-0.7%$145.29$145.34$142.00884,118
$145.04-11.03-7.1%$154.66$154.74$143.901,593,141
$156.07-0.24-0.2%$156.13$158.08$154.24832,350
$156.31-3.27-2.0%$158.83$160.82$156.04524,795
$159.58+3.77+2.4%$157.65$164.79$157.38653,892
$155.81-1.33-0.8%$157.54$158.66$154.50781,732
$157.14-4.65-2.9%$160.43$160.43$156.09873,100
$161.79-0.43-0.3%$163.44$169.96$160.27802,600
$162.22+5.90+3.8%$156.44$164.00$155.18893,200
$156.32-9.68-5.8%$166.01$166.55$155.691,328,600
$166.00-2.35-1.4%$169.50$170.80$165.02663,000
$168.35-1.73-1.0%$170.18$170.64$166.12894,500
$170.08-2.89-1.7%$170.09$172.28$166.211,073,600
$172.97-1.37-0.8%$174.00$177.91$172.48887,300
$174.34-2.74-1.5%$176.52$176.52$169.301,367,800
$177.08-2.17-1.2%$179.25$179.70$175.73858,900
$179.25-2.82-1.5%$182.55$182.55$175.46981,400
$182.07-2.32-1.3%$184.39$185.67$181.75660,200
$184.39-1.75-0.9%$186.51$188.00$184.001,033,900
$186.14-7.75-4.0%$191.41$194.25$182.101,577,600
$193.89-1.20-0.6%$194.98$198.96$193.11707,400
$195.09-0.94-0.5%$197.68$201.42$194.35838,200
$196.03+2.58+1.3%$193.02$197.11$190.72386,100
$193.45-9.65-4.8%$204.01$204.70$189.05913,000
$203.10-2.39-1.2%$205.68$207.01$202.52299,800
$205.49-2.29-1.1%$208.17$210.85$203.38543,500
$207.78-6.50-3.0%$212.05$213.27$206.92869,300
$214.28+2.31+1.1%$215.59$216.47$208.63681,400
$211.97+7.90+3.9%$202.95$214.64$201.94644,900
$204.07-12.51-5.8%$215.02$215.02$203.78591,300
$216.58-4.17-1.9%$221.93$223.29$216.00718,800
$220.75+9.635+4.6%$212.71$229.62$212.441,228,400
$211.12+0.485+0.2%$210.63$211.65$208.01526,400
$210.63+2.81+1.4%$207.97$211.22$205.76428,400
$207.82+1.14+0.6%$205.00$210.86$202.00385,800
$206.68-1.67-0.8%$207.01$208.51$205.49438,200
$208.35-1.57-0.7%$209.32$210.59$206.60558,800
$209.92+7.09+3.5%$203.11$210.55$201.55608,200
$202.83+4.31+2.2%$199.71$205.94$199.71656,300
$198.52-0.50-0.3%$199.00$200.74$197.05503,700
$199.02-7.25-3.5%$205.70$205.70$199.00441,200
$206.27-0.88-0.4%$205.00$208.26$203.71586,300
$207.15+1.67+0.8%$204.48$210.68$203.70378,400
$205.48+0.080.0%$207.58$209.53$200.19731,500
$205.40-2.37-1.1%$207.00$208.09$205.09293,200
$207.77-0.26-0.1%$207.22$210.87$206.50734,900
$208.03-10.17-4.7%$216.50$217.85$206.26620,900
Ticker
Hanover:19X
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Hanover
Currency
EUR

What changed lately

Latest news

All Axsome Therapeutics, Inc. news

Axsome Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
33 in the last 12 months · 230 in all · newest Nov 19, 2026 · oldest 2019
Calls
27 calls with a replay · 27 with a transcript · latest Nov 2, 2026
Decks
48 decks · latest November 2026

Where Axsome Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AXSM · Home listingNASDAQUnited StatesUSD
LS Exchange:A2AA7BLS ExchangeGermanyEUR
Tradegate:19XTradegateGermanyEUR
gettex:19XgettexGermanyEUR
BMV:AXSMBMVMexicoMXN
LSE:0HKFLSEUnited KingdomUSD
Lang & Schwarz:A2AA7BLang & SchwarzGermanyEUR
Milan:1AXSMMilanItalyEUR
Frankfurt:19XFrankfurtGermanyEUR
BIVA:AXSMBIVAMexicoMXN
BOATS:AXSMBOATSUnited StatesUSD
BX Swiss:AXSMBX SwissSwitzerlandCHF
Stuttgart:19XStuttgartGermanyEUR
Dusseldorf:19XDusseldorfGermanyEUR
Hamburg:19XHamburgGermanyEUR
Munich:19XMunichGermanyEUR
Hanover:19X · This pageHanoverGermanyEUR
Xetra:19XXetraGermanyEUR

Valuation

EV/sales 7.7× against a median of 56.2×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$6.68B USD
P/E
Loss
EV/sales
7.7×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
64.5×
Gross margin
Not reported
Operating margin
−17.4%
Net margin
−18.2%
Debt to equity
1.8×
Beta vs S&P 500
0.69

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Axsome Therapeutics, Inc. · NASDAQ:AXSMUS$6.80BUS$6.68Bn/a7.7×n/a64.5×−18.2%1.8×0.69
Alkermes plc · NASDAQ:ALKSUS$7.55BUS$8.31Bn/a4.7×57.3×4.0×−0.0%0.8×0.80
CG Oncology, Inc. · NASDAQ:CGONUS$7.10BUS$6.12Bn/a992×n/a7.2×n/a0.0×0.83
Cytokinetics, Incorporated · NASDAQ:CYTKUS$7.07BUS$6.36Bn/a56.2×n/an/a−686.6%n/a0.93
Akeso, Inc. · HKEX:9926US$6.66BUS$6.04Bn/a13.5×n/a5.2×−36.4%0.6×n/a
Immunovant, Inc. · NASDAQ:IMVTUS$6.57BUS$5.85Bn/a825×n/a10.0×n/a0.0×1.46
Oruka Therapeutics, Inc. · NASDAQ:ORKAUS$6.50BUS$5.58Bn/an/an/a5.4×n/a0.0×1.30
ImmunityBio, Inc. · NASDAQ:IBRXUS$6.40BUS$6.10Bn/a33.4×n/an/a−607.8%n/a1.50
Kodiak Sciences Inc · NASDAQ:KODUS$6.35BUS$6.31Bn/an/an/a505×n/a3.7×1.58
Abivax SA · EURONEXT:ABVXUS$6.05BUS$5.60Bn/an/an/a15.1×n/a0.0×n/a
Scholar Rock Holding Corporation · NASDAQ:SRRKUS$5.87BUS$5.65Bn/a9,921×n/a34.8×n/a1.2×0.91
Median of the othersUS$6.54BUS$6.07B56.2×57.3×8.6×−322.1%0.3×1.12

Forecasts

18 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
264.62 USD · Analysts' mean
EPS, year to Dec 2026
-2.46 · 13 analysts
Revenue, year to Dec 2026
954.3M · 21 analysts

Team and board

Officers

OfficerRole
Herriot TabuteauCHIEF EXECUTIVE OFFICER
Nick PizzieCHIEF FINANCIAL OFFICER
Mark JacobsonCHIEF OPERATING OFFICER
Hunter MurdockGENERAL COUNSEL
Ashley DongSenior Director, Investor Relations
Darren OplandSenior Director, Corporate Communications
Ari MaizelCHIEF COMMERCIAL OFFICER

Board

DirectorRole
Herriot TabuteauCHIEF EXECUTIVE OFFICER
Mark ColemanDIRECTOR
Mark SaadDIRECTOR
Roger JeffsDIRECTOR
Susan MahonyDIRECTOR

Events

Calls

CallWhenStatus
Axsome Therapeutics (NASDAQ:AXSM) Q3 2026 Earnings CallMon, Nov 02, 2026 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings CallMon, Aug 10, 2026 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q1 2026 Earnings CallMon, May 04, 2026 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q4 2025 Earnings CallMon, Feb 23, 2026 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q3 2025 Earnings CallMon, Nov 03, 2025 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q2 2025 Earnings CallMon, Aug 04, 2025 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q1 2025 Earnings CallTue, May 06, 2025 · 4:30 PM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q4 2024 Earnings CallMon, Jan 13, 2025 · 1:00 PM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q3 2024 Earnings CallTue, Nov 12, 2024 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q2 2024 Earnings CallMon, Aug 05, 2024 · 8:00 AM ETReplay
All 27 calls
CallWhenStatus
Axsome Therapeutics (NASDAQ:AXSM) Q1 2024 Earnings CallMon, May 06, 2024 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q4 2023 Earnings CallThu, Jan 04, 2024 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q3 2023 Earnings CallMon, Nov 06, 2023 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q2 2023 Earnings CallMon, Aug 07, 2023 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q1 2023 Earnings CallMon, May 08, 2023 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q4 2022 Earnings CallMon, Feb 27, 2023 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q3 2022 Earnings CallMon, Nov 07, 2022 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q2 2022 Earnings CallTue, Aug 09, 2022 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q1 2022 Earnings CallMon, May 02, 2022 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q4 2021 Earnings CallTue, Mar 01, 2022 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q3 2021 Earnings CallMon, Nov 08, 2021 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q2 2021 Earnings CallMon, Aug 09, 2021 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q1 2021 Earnings CallMon, May 10, 2021 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q4 2020 Earnings CallMon, Mar 01, 2021 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q3 2020 Earnings CallThu, Nov 05, 2020Replay
Axsome Therapeutics (NASDAQ:AXSM) Q2 2020 Earnings CallMon, Aug 10, 2020 · 8:00 AM ETReplay
Axsome Therapeutics (NASDAQ:AXSM) Q1 2020 Earnings CallFri, May 08, 2020Replay

Results days

QuarterResultsShare move
Q3 2026Nov 2, 2026 · Before open−5.8%
Q2 2026Aug 10, 2026 · Before open+3.8%
Q1 2026May 4, 2026 · Before open+8.3%
Q4 2025Feb 23, 2026−7.5%
Q3 2025Nov 3, 2025 · Before open+0.6%
Q2 2025Aug 4, 2025 · Before open+3.4%
Q1 2025May 5, 2025 · Before open+3.8%
Q4 2024Feb 18, 2025 · Before open−2.3%
Q3 2024Nov 12, 2024 · Before open+9.3%
Q2 2024Aug 5, 2024 · Before open−1.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 6, 2024 · Before open+1.5%
Q4 2023Feb 20, 2024 · Before open−12.6%
Q3 2023Nov 6, 2023 · Before open−4.2%
Q2 2023Aug 7, 2023 · Before open−3.5%
Q1 2023May 8, 2023 · Before open+5.4%
Q4 2022Feb 27, 2023 · Before open+5.0%
Q3 2022Nov 7, 2022 · Before open−0.5%
Q2 2022Aug 9, 2022 · Before open+3.4%
Q1 2022May 2, 2022 · Before open+7.2%
Q4 2021Mar 1, 2022 · Before open+10.2%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck50 slidesNovember 2026
Q2 2026 Earnings PresentationEarnings46 slidesAug 10, 2026
Q1 2026 Earnings PresentationEarnings49 slidesMay 4, 2026
Investor Presentation (May 2026)Investor deck26 slidesMay 1, 2026
Q4 2025 Earnings PresentationEarnings47 slidesFeb 23, 2026
Q3 2025 Earnings PresentationEarnings46 slidesNov 3, 2025
Q2 2025 Earnings PresentationEarnings45 slidesAug 4, 2025
Q1 2025 Earnings PresentationEarnings26 slidesMay 6, 2025
Q1 2025 Earnings PresentationEarnings45 slidesMay 5, 2025
FY2024 Earnings PresentationEarnings46 slidesFeb 18, 2025
All 48 decks
DeckKindSlidesDate
Technical Presentation (December 2024)Technical31 slidesDec 30, 2024
Q3 2024 Earnings PresentationEarnings48 slidesNov 12, 2024
Technical Presentation (March 2024)Technical25 slidesMar 25, 2024
Investor Presentation (February 2024)Investor deck41 slidesFeb 20, 2024
Investor Presentation (January 2024)Investor deck41 slidesJan 8, 2024
Investor Day (December 2023)Investor day95 slidesDec 7, 2023
Investor Presentation (August 2023)Investor deck35 slidesAug 15, 2023
Investor Presentation (June 2023)Investor deck34 slidesJun 13, 2023
Corporate Update (June 2022)Corporate update76 slidesJun 28, 2022
Merger or Acquisition (March 2022)Merger or acquisition12 slidesMar 28, 2022
American Headache Society Virtual Annual Scientific Meeting 2021Conference11 slidesJune 2021
SVB Leerink Global Healthcare Conference 2021Conference22 slidesFeb 24, 2021
Q3 2020 Earnings PresentationEarnings21 slidesNov 5, 2020
2020 American Academy of Neurology Science Highlights Emerging Science PresentationConference16 slidesSep 23, 2020
Investor Presentation (September 2020)Investor deck21 slidesSep 16, 2020
Q1 2020 Earnings PresentationEarnings16 slidesMay 8, 2020
Technical Presentation (May 2020)Technical15 slidesMay 2020
Technical Presentation (April 2020)Technical23 slidesApr 27, 2020
Technical Presentation (April 2020)Technical27 slidesApr 6, 2020
STRIDE-1 Phase 3 Trial of AXS-05 in TRD Topline Results Conference Call (March 2020)Conference24 slidesMar 30, 2020
Investor Presentation (March 2020)Investor deck28 slidesMar 12, 2020
Merger or Acquisition (January 2020)Merger or acquisition16 slidesJan 13, 2020
Technical Presentation (December 2019)Technical26 slidesDec 30, 2019
GEMINI Phase 3 Trial of AXS-05 in MDD Topline Results Conference Call (December 2019)Conference22 slidesDec 16, 2019
Technical Presentation (December 2019)Technical26 slidesDec 3, 2019
Investor Presentation (November 2019)Investor deck30 slidesNov 7, 2019
ASCP 2019 Oral SessionConference17 slidesMay 2019
Investor Presentation (March 2019)Investor deck41 slidesMar 14, 2019
Technical Presentation (January 2019)Technical22 slidesJan 7, 2019
Investor Presentation (January 2019)Investor deck41 slidesJan 7, 2019
Investor Presentation (November 2018)Investor deck40 slidesNov 9, 2018
Investor Presentation (October 2018)Investor deck41 slidesOct 17, 2018
Investor Presentation (August 2018)Investor deck34 slidesAug 8, 2018
Investor Presentation (March 2018)Investor deck32 slidesMar 7, 2018
Investor Presentation (January 2018)Investor deck33 slidesJan 9, 2018
Investor Presentation (September 2017)Investor deck36 slidesSep 18, 2017
Investor Presentation (March 2017)Investor deck34 slidesMar 14, 2017
Investor Presentation (July 2016)Investor deck31 slidesJul 13, 2016

Open Decks

Financings

RaiseDate
Strategic investment of common stock
Closed: US$15M raised · US$107.14 a share
Buyers: Blackstone ($15 million of Axsome common stock)
May 13, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$9.00 a share on Nov 19, 2015.

Price
US$9.00 a share
Shares offered
5,666,667 shares of common stock
Offering size
US$51 million
Underwriters' option
Up to 850,000 more shares
Listing
AXSM on the Nasdaq Capital Market
Underwriters
Ladenburg Thalmann, Cantor Fitzgerald & Co., Brean Capital · In the order on the cover
Shares delivered
On or about Nov 24, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceAug 25, 2015
Filed publiclyOct 13, 2015
Amended onceNov 2, 2015
Shares registered with an exchangeNov 16, 2015
Declared effective by the SECNov 19, 2015
Final prospectus, with the priceNov 19, 2015

Open IPO · From the cover of the final prospectus (424B4) filed Nov 19, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue638.5M385.7M270.6M0
Cost of revenue5.20M
Gross profit-5.20M
Research and development183.3M187.1M97.9M57.9M58.1M70.2M53.6M23.5M20.0M21.2M
Selling, general and administrative570.6M411.4M323.1M159.3M66.6M28.9M
Operating income-166.8M-280.6M-231.8M-179.8M-124.7M-99.1M-67.2M-32.8M-27.2M-27.5M
Depreciation and amortization503.0K532.0K459.0K263.0K76.0K23.9K37.3K48.9K42.6K20.5K
EBITDA-166.3M-280.0M-231.4M-179.5M-124.6M-99.1M-67.2M-32.8M-27.1M-27.5M
Interest expense-15.9M-21.6M-20.0M-9.66M
Income before tax-183.7M-287.1M-238.3M-187.1M-130.4M
Income tax-530.0K85.0K960.0K0000000
Net income-183.2M-287.2M-239.2M-187.1M-130.4M-102.9M-68.3M-31.0M-28.9M-27.2M
Earnings per share, basic-3.68-5.99-5.27-4.60-3.47-2.77-2.01-1.15-1.27-1.42
Earnings per share, diluted-3.68-5.99-5.27-4.60-3.47-2.77-2.01-1.15-1.27-1.42

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents322.9M315.4M386.2M200.8M86.5M183.9M220.0M14.0M34.0M36.6M
Receivables224.5M142.0M94.8M37.7M
Inventory27.9M15.7M15.1M4.32M
Current assets589.0M485.1M504.3M245.6M86.5M184.0M220.4M15.2M35.3M38.0M
Property, plant and equipment562.0K584.0K846.0K722.0K283.8K52.6K30.6K51.8K68.1K100.7K
Goodwill12.0M12.0M12.0M10.3M
Total assets689.8M568.5M588.2M331.5M87.8M186.1M220.5M15.4M35.6M38.2M
Accounts payable65.5M72.0M40.7M38.6M13.1M13.5M10.9M3.69M3.44M4.08M
Current liabilities378.8M230.1M138.9M96.6M23.1M23.4M24.5M10.8M12.2M7.17M
Long-term debt117.7M180.7M178.1M94.3M49.1M48.3M17.3M3.62M6.66M9.47M
Total debt187.7M180.7M178.1M94.3M49.1M48.3M19.9M6.91M9.93M9.74M
Total liabilities601.5M511.5M397.3M221.9M72.2M72.3M41.8M14.4M18.8M16.6M
Shareholders' equity88.3M57.0M191.0M109.6M15.6M113.8M178.7M937.9K16.7M21.6M
Shares outstanding50.9M48.7M47.4M43.5M37.8M37.4M36.9M30.1M25.5M19.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-93.4M-128.4M-145.1M-116.5M-108.2M-78.5M-46.4M-30.1M-26.5M-21.3M
Capital spending-480.0K-270.0K-582.0K-702.0K-308.0K-45.9K-16.1K-32.7K-9.90K-104.6K
Free cash flow-93.9M-128.7M-145.7M-117.2M-108.5M-78.5M-46.4M-30.1M-26.5M-21.4M
Cash from investing-480.0K-270.0K-582.0K-53.7M-308.0K-45.9K-16.1K-32.7K-9.90K-104.6K
Cash from financing101.5M57.8M331.0M284.6M11.1M42.4M252.4M10.0M23.9M9.97M
Change in cash7.58M-70.8M185.4M114.4M-97.4M-36.1M206.0M-20.1M-2.60M-11.4M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 2, 2026Quarterly reportSEC
8-K · Current reportNov 2, 2026ResultsSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026ResultsSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
144 · Notice of proposed saleAug 6, 2026Other filingsSEC
144 · Notice of proposed saleAug 5, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJul 15, 2026Current reportSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
144 · Notice of proposed saleJun 11, 2026Other filingsSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
144 · Notice of proposed saleJun 10, 2026Other filingsSEC
144 · Notice of proposed saleJun 10, 2026Other filingsSEC
144 · Notice of proposed saleJun 10, 2026Other filingsSEC
144 · Notice of proposed saleJun 9, 2026Other filingsSEC
8-K · Current reportJun 9, 2026Management or board changeSEC
8-K · Current reportJun 9, 2026Meeting outcomeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
144 · Notice of proposed saleJun 9, 2026Other filingsSEC
144 · Notice of proposed saleJun 9, 2026Other filingsSEC
8-K · Current reportJun 3, 2026Current reportSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
144 · Notice of proposed saleJun 2, 2026Other filingsSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 29, 2026Other filingsSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedMay 5, 2026Other filingsSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
10-Q · Quarterly reportMay 4, 2026Quarterly reportSEC
8-K · Current reportMay 4, 2026ResultsSEC
8-K · Current reportApr 30, 2026Current reportSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
144 · Notice of proposed saleApr 22, 2026Other filingsSEC
8-K · Current reportApr 1, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 26, 2026Other filingsSEC
144 · Notice of proposed saleFeb 26, 2026Other filingsSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
10-K · Annual reportFeb 23, 2026Annual reportSEC
8-K · Current reportFeb 23, 2026ResultsSEC
8-K · Current reportFeb 17, 2026Current reportSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
144 · Notice of proposed saleJan 21, 2026Other filingsSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
144 · Notice of proposed saleJan 7, 2026Other filingsSEC
144 · Notice of proposed saleJan 6, 2026Other filingsSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
144 · Notice of proposed saleDec 31, 2025Other filingsSEC
8-K · Current reportDec 31, 2025Current reportSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
144 · Notice of proposed saleDec 2, 2025Other filingsSEC
144 · Notice of proposed saleNov 5, 2025Other filingsSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
144 · Notice of proposed saleNov 4, 2025Other filingsSEC
144 · Notice of proposed saleNov 3, 2025Other filingsSEC
S-3ASR · Registration statementNov 3, 2025Offer documentSEC
10-Q · Quarterly reportNov 3, 2025Quarterly reportSEC
8-K · Current reportNov 3, 2025ResultsSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
144 · Notice of proposed saleOct 8, 2025Other filingsSEC
144 · Notice of proposed saleOct 7, 2025Other filingsSEC
144 · Notice of proposed saleOct 6, 2025Other filingsSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
144 · Notice of proposed saleSep 22, 2025Other filingsSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
144 · Notice of proposed saleSep 16, 2025Other filingsSEC
144 · Notice of proposed saleSep 16, 2025Other filingsSEC
144 · Notice of proposed saleSep 15, 2025Other filingsSEC
144 · Notice of proposed saleSep 12, 2025Other filingsSEC
4 · Change in ownershipSep 9, 2025Insider tradeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
144 · Notice of proposed saleSep 5, 2025Other filingsSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
144 · Notice of proposed saleSep 2, 2025Other filingsSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
144 · Notice of proposed saleAug 29, 2025Other filingsSEC
144 · Notice of proposed saleAug 28, 2025Other filingsSEC
144 · Notice of proposed saleAug 27, 2025Other filingsSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
144 · Notice of proposed saleAug 26, 2025Other filingsSEC
144 · Notice of proposed saleAug 22, 2025Other filingsSEC
8-K · Current reportAug 20, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 7, 2025Offer documentSEC
10-Q · Quarterly reportAug 4, 2025Quarterly reportSEC
8-K · Current reportAug 4, 2025ResultsSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
144 · Notice of proposed saleJun 23, 2025Other filingsSEC
144 · Notice of proposed saleJun 20, 2025Other filingsSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
144 · Notice of proposed saleJun 18, 2025Other filingsSEC
144 · Notice of proposed saleJun 17, 2025Other filingsSEC
144 · Notice of proposed saleJun 16, 2025Other filingsSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
8-K · Current reportJun 10, 2025Current reportSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
144 · Notice of proposed saleJun 9, 2025Other filingsSEC
8-K · Current reportJun 9, 2025Current reportSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
144 · Notice of proposed saleMay 28, 2025Other filingsSEC
144 · Notice of proposed saleMay 28, 2025Other filingsSEC
144 · Notice of proposed saleMay 27, 2025Other filingsSEC
144 · Notice of proposed saleMay 27, 2025Other filingsSEC
8-K · Current reportMay 27, 2025Current reportSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
144 · Notice of proposed saleMay 20, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 13, 2025Material contractSEC
10-Q · Quarterly reportMay 5, 2025Quarterly reportSEC
8-K · Current reportMay 5, 2025ResultsSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
8-K · Current reportApr 1, 2025Current reportSEC
8-K · Current reportMar 25, 2025Current reportSEC
8-K · Current reportMar 5, 2025Current reportSEC
8-K · Current reportMar 3, 2025Current reportSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
10-K · Annual reportFeb 18, 2025Annual reportSEC
8-K · Current reportFeb 18, 2025ResultsSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleFeb 13, 2025Other filingsSEC
8-K · Current reportFeb 10, 2025Current reportSEC
8-K · Current reportJan 30, 2025Current reportSEC
8-K · Current reportJan 13, 2025ResultsSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
8-K · Current reportDec 30, 2024Current reportSEC
8-K · Current reportNov 26, 2024Current reportSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
8-K · Current reportOct 1, 2024Material contractSEC
4 · Change in ownershipSep 11, 2024Insider tradeSEC
144 · Notice of proposed saleSep 11, 2024Other filingsSEC
8-K · Current reportSep 4, 2024Current reportSEC
8-K · Current reportAug 21, 2024Current reportSEC
4 · Change in ownershipAug 9, 2024Insider tradeSEC
144 · Notice of proposed saleAug 9, 2024Other filingsSEC
S-8 · Registration statement for employee plansAug 5, 2024Offer documentSEC
10-Q · Quarterly reportAug 5, 2024Quarterly reportSEC
8-K · Current reportAug 5, 2024ResultsSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC

This page holds 200 of 672 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Axsome Therapeutics, Inc.’s releases · as of Oct 26, 2026

Common shares
52,599,985
Fully diluted
52,599,985

Fully diluted

LineSharesAs of
Common shares52,599,985Oct 26, 2026

Share count over time

CountShares
Oct 26, 202652,599,985

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard4.34M8.3%US$801MSep 30, 2026
BlackRock3.45M6.6%US$636MSep 30, 2026
Invesco1.93M3.7%US$356MSep 30, 2026
Fidelity1.44M2.7%US$266MSep 30, 2026
Millennium1.32M2.5%US$244MSep 30, 2026
Two Sigma1.11M2.1%US$205MSep 30, 2026
Franklin Templeton1.03M2.0%US$155MSep 30, 2026
Geode Capital1.01M1.9%US$186MSep 30, 2026
UBS1.01M1.9%US$186MSep 30, 2026
State Street823K1.6%US$152MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Deep Track Capital, LP800K1.5%US$148MSep 30, 2026
Bank of America741K1.4%US$137MSep 30, 2026
Westfield Capital Management Co LP726K1.4%US$134MSep 30, 2026
T. Rowe Price667K1.3%US$123MSep 30, 2026
Alethea Capital Management, LLC649K1.2%US$120MSep 30, 2026
D. E. Shaw & Co., Inc.631K1.2%US$116MSep 30, 2026
Ameriprise614K1.2%US$113MSep 30, 2026
Morgan Stanley592K1.1%US$109MSep 30, 2026
AQR Capital Management LLC561K1.1%US$104MSep 30, 2026
First Trust553K1.1%US$102MSep 30, 2026
Wellington493K0.94%US$90.9MSep 30, 2026
Federated Hermes, Inc.482K0.92%US$88.9MSep 30, 2026
Pictet Asset Management Holding SA482K0.92%US$88.8MSep 30, 2026
Schwab476K0.91%US$87.9MSep 30, 2026
Nomura463K0.88%US$85.3MSep 30, 2026
Sofinnova Investments, Inc.446K0.85%US$82.2MSep 30, 2026
Hood River Capital Management LLC408K0.78%US$75.3MSep 30, 2026
Qube Research & Technologies Ltd370K0.70%US$68.2MSep 30, 2026
Principal310K0.59%US$57.2MSep 30, 2026
Eventide Asset Management, LLC300K0.57%US$55.3MSep 30, 2026
Samlyn Capital, LLC289K0.55%US$53.3MSep 30, 2026
Northern Trust270K0.51%US$49.9MSep 30, 2026
Marshall Wace, LLP261K0.50%US$48.1MSep 30, 2026
Cannell & Spears LLC260K0.49%US$47.9MSep 30, 2026
Assenagon Asset Management S.A.251K0.48%US$46.2MSep 30, 2026
Integral Health Asset Management, LLC250K0.48%US$46.1MSep 30, 2026
Bellevue Group AG248K0.47%US$45.7MSep 30, 2026
Loomis Sayles & Co L P244K0.46%US$44.9MSep 30, 2026
CPP Investments243K0.46%US$44.9MSep 30, 2026
PFM Health Sciences, LP222K0.42%US$41MSep 30, 2026
Nuveen220K0.42%US$40.5MSep 30, 2026
Renaissance Technologies206K0.39%US$37.9MSep 30, 2026
BNY205K0.39%US$37.9MSep 30, 2026
Driehaus Capital Management LLC204K0.39%US$37.6MSep 30, 2026
Frontier Capital Management Co LLC189K0.36%US$34.8MSep 30, 2026
BNP Paribas182K0.35%US$33.6MSep 30, 2026
Defilade Capital Management, L.P.175K0.33%US$32.3MSep 30, 2026
Logos Global Management LP175K0.33%US$32.3MSep 30, 2026
Orbimed Advisors LLC171K0.32%US$31.5MSep 30, 2026
DWS171K0.32%US$31.4MSep 30, 2026

This page holds 50 of 454 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.39M2.6%US$340MJun 30, 2026
Vanguard Small-Cap Index Fund1M1.9%US$246MJun 30, 2026
Vanguard Small-Cap Growth Index Fund578K1.1%US$142MJun 30, 2026
Vanguard Explorer Fund531K1.0%US$116MJul 31, 2026
Vanguard Extended Market Index Fund496K0.94%US$121MJun 30, 2026
Invesco Discovery Fund469K0.89%US$110MMay 31, 2026
Nomura Small Cap Core Fund430K0.82%US$101MMay 29, 2026
First Trust NYSE Arca Biotechnology Index Fund426K0.81%US$104MJun 30, 2026
iShares Biotechnology ETF305K0.58%US$74.7MJun 30, 2026
Franklin Dynatech Fund300K0.57%US$73.4MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Select Biotechnology Portfolio287K0.54%US$67.2MMay 31, 2026
Eventide Gilead Fund257K0.49%US$62.9MJun 30, 2026
iShares Russell Mid-Cap Growth ETF255K0.48%US$62.4MJun 30, 2026
Fidelity Extended Market Index Fund218K0.41%US$51.2MMay 31, 2026
Vanguard Russell 2000 Index Fund213K0.40%US$49.9MMay 31, 2026
Putnam Small Cap Growth Fund213K0.40%US$52MJun 30, 2026
Federated Hermes MDT Mid Cap Growth Fund206K0.39%US$44.9MJul 31, 2026
Schwab U.S. Small-Cap ETF203K0.39%US$47.7MMay 31, 2026
Select Health Care Portfolio190K0.36%US$44.6MMay 31, 2026
Hood River Small-Cap Growth Fund190K0.36%US$46.4MJun 30, 2026
iShares Russell Mid-Cap ETF177K0.34%US$43.3MJun 30, 2026
Fidelity Small Cap Growth Fund173K0.33%US$37.6MJul 31, 2026
iShares Russell 1000 Growth ETF165K0.31%US$40.3MJun 30, 2026
Fidelity Mid Cap Index Fund165K0.31%US$35.9MJul 31, 2026
JNL/Invesco Small Cap Growth Fund164K0.31%US$40.1MJun 30, 2026
Columbia Small Cap Growth Fund163K0.31%US$38.3MMay 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund163K0.31%US$38.2MMay 31, 2026
Invesco Discovery Mid Cap Growth Fund159K0.30%US$34.8MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.151K0.29%US$37MJun 30, 2026
Invesco Small Cap Growth Fund151K0.29%US$36.9MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF150K0.28%US$36.6MJun 30, 2026
SmallCap Fund133K0.25%US$28.9MJul 31, 2026
Loomis Sayles Small Cap Growth Fund130K0.25%US$31.7MJun 30, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund119K0.23%US$25.9MJul 31, 2026
iShares U.S. Pharmaceuticals ETF112K0.21%US$27.5MJun 30, 2026
Vanguard Health Care Index Fund105K0.20%US$24.7MMay 31, 2026
Bridge Builder Small/Mid Cap Growth Fund99,5380.19%US$24.4MJun 30, 2026
Voya Small Cap Growth Fund99,2160.19%US$23.3MMay 31, 2026
First Trust Health Care AlphaDEX Fund96,9540.18%US$21.1MJul 31, 2026
T. Rowe Price New Horizons Fund, Inc.95,9930.18%US$23.5MJun 30, 2026
Fidelity Small Cap Growth K6 Fund89,5350.17%US$19.5MJul 31, 2026
Invesco Small Cap Equity Fund89,0400.17%US$21.8MJun 30, 2026
Invesco Health Care Fund87,7000.17%US$19.1MJul 31, 2026
Invesco Main Street Small Cap Fund82,7980.16%US$20.3MJun 30, 2026
iShares U.S. Small-Cap Equity Factor ETF82,0070.16%US$17.9MJul 31, 2026
Fidelity Total Market Index Fund80,9120.15%US$19MMay 31, 2026
Fidelity Advisor Health Care Fund80,0000.15%US$17.4MJul 31, 2026
ClearBridge Small Cap Growth Fund76,8000.15%US$16.7MJul 31, 2026
Invesco Small Cap Growth Portfolio71,1100.14%US$17.4MJun 30, 2026
Federated Hermes MDT Small Cap Core Fund70,3030.13%US$15.3MJul 31, 2026

This page holds 50 of 389 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Jacobson Mark L.
Officer: Chief Operating Officer
Sale10,000USD 208.65US$2.09MSep 3, 2026
Tabuteau Herriot
Director, Officer: Chief Executive Officer, 10% owner
Sale4,660USD 213.95US$997KAug 6, 2026
Tabuteau Herriot
Director, Officer: Chief Executive Officer, 10% owner
Sale45,004USD 212.01US$9.54MAug 5, 2026
Tabuteau Herriot
Director, Officer: Chief Executive Officer, 10% owner
Sale49,666USD 240.25US$11.9MJul 1, 2026
Jeffs Roger
Director
Sale286USD 249.12US$71,248Jun 11, 2026
Jeffs Roger
Director
Sale286USD 246.18US$70,407Jun 10, 2026
Coleman Mark
Director
Sale643USD 249.00US$160KJun 10, 2026
Mahony Susan
Director
Sale300USD 246.18US$73,854Jun 10, 2026
Mahony Susan
Director
Sale300USD 237.21US$71,163Jun 9, 2026
Pizzie Nick
Officer: Chief Financial Officer
Sale33,000USD 240.09US$7.92MJun 9, 2026
All 17 trades
TradeTradeSharesPriceValueDate
Tabuteau Herriot
Director, Officer: Chief Executive Officer, 10% owner
Sale49,670USD 241.01US$12MJun 9, 2026
Coleman Mark
Director
Sale5,537USD 223.39US$1.24MJun 2, 2026
Coleman Mark
Director
Sale6,000USD 230.30US$1.38MJun 1, 2026
Coleman Mark
Director
Sale6,000USD 233.46US$1.4MMay 29, 2026
Jacobson Mark L.
Officer: Chief Operating Officer
Sale233USD 228.18US$53,166May 5, 2026
Jacobson Mark L.
Officer: Chief Operating Officer
Sale4,517USD 227.94US$1.03MMay 4, 2026
Maizel Ari
Officer: Chief Commercial Officer
Sale7,500USD 182.42US$1.37MApr 22, 2026

Big stakes

StakeStakeSharesDateFiling
BlackRock, Inc.5.30%2.74MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Myrtle S Potter
Other companies: Ginkgo Bioworks Holdings, Inc. (Director · Since at least Jun 13, 2024); Guardant Health, Inc. (Director · Since at least Oct 15, 2021); Immunovant, Inc. (Director · Dec 18, 2019 – Dec 18, 2019 · Past); Arbutus Biopharma Corporation (Director · Oct 18, 2018 – Aug 17, 2019 · Past); Sio Gene Therapies Inc (Director · Sep 26, 2018 – Apr 15, 2019 · Past); Urovant Sciences Ltd (Director · Sep 26, 2018 – Mar 29, 2021 · Past); Myovant Sciences Ltd (Director · Sep 20, 2018 – Mar 10, 2023 · Past); Insmed Incorporated (Director · Dec 11, 2014 – May 15, 2018 · Past); Everyday Health Inc (Director · Mar 27, 2014 – Dec 3, 2016 · Past); Rite Aid Corporation (Director · Nov 29, 2013 – Oct 3, 2017 · Past)
Director · Jun 16, 2017 – Jun 7, 2019 · Past
Roger Jeffs
Other companies: Liquidia Corporation (Chief Executive Officer · Since at least Nov 18, 2020); Sio Gene Therapies Inc (Director · Feb 8, 2018 – Apr 15, 2019 · Past); Albireo Pharma Inc (Director · Sep 27, 2017 – Jun 24, 2021 · Past); Dova Pharmaceuticals Inc (Director · Jun 28, 2017 – Nov 12, 2019 · Past); Sangamo Therapeutics, Inc. (Director · Jun 26, 2017 – Sep 7, 2018 · Past); United Therapeutics Corporation (President & Co-CEO, Director · Jan 5, 2006 – Mar 15, 2016 · Past)
DIRECTOR · Since at least Nov 19, 2015
Susan Mahony
Other companies: Zymeworks Inc. (Director · Since at least Jun 3, 2019); Assembly Biosciences, Inc. (Director · Since at least Dec 14, 2017); Eli Lilly and Company (SVP & Pres., Lilly Oncology · Jul 28, 2015 – Apr 13, 2018 · Past)
DIRECTOR · Since at least Oct 10, 2023
David C Marek
Other companies: Myovant Sciences Ltd (Principal Executive Officer, Director · Jan 4, 2021 – Mar 10, 2023 · Past); WebMD Health Corp (Executive Vice President · Sep 4, 2012 – Sep 4, 2013 · Past)
Chief Commercial Officer · Sep 4, 2019 – Mar 17, 2020 · Past
John Golubieski
Other companies: BioDelivery Sciences International Inc (See Remarks · Oct 25, 2021 – Mar 22, 2022 · Past)
Chief Financial Officer · Aug 4, 2017 – Aug 4, 2017 · Past
ari MaizelCHIEF COMMERCIAL OFFICER · Since at least Oct 14, 2024
Ashley DongSenior Director, Investor Relations · Since at least Nov 3, 2026
Darren OplandSenior Director, Corporate Communications · Since at least Nov 3, 2026
Herriot TabuteauChief Executive Officer, Director · Since at least Sep 12, 2025
Hunter MurdockGENERAL COUNSEL · Since at least Jun 13, 2022
All 15 people
PersonSeat
Mark ColemanDIRECTOR · Since at least Nov 19, 2015
Mark JacobsonCHIEF OPERATING OFFICER · Since at least May 27, 2025
Mark SaadDirector · Since at least Jun 8, 2026
Nick PizzieCHIEF FINANCIAL OFFICER · Since at least Jun 9, 2026
Nick PizzieChief Financial Officer · Since at least Jan 22, 2026

Open People

Log in to ask 6ix AI your own questions about Axsome Therapeutics, Inc.